Dr. Amol Kulkarni
Department of Chemistry
Dr. Amol Kulkarni is a synthetic medicinal chemist whose research focuses on the design and development of novel small molecules to inhibit neuroinflammation in substance abuse disorders. His laboratory integrates computational approaches with medicinal chemistry and organic synthesis to generate and optimize compounds targeting the NLRP3 inflammasome, a key mediator of neuroinflammatory processes.
Project Description
My laboratory focuses on the preclinical development of small molecules targeting neuroinflammation-associated substance use disorders. We also design and synthesize small molecule probes to investigate neuroimmune interactions in substance abuse and elucidate the mechanisms by which neuroinflammation contributes to disease pathophysiology and neurodegeneration. Our current research encompasses cocaine and opioid use disorders.
A common pathological feature across these disorders is neuroinflammation involving the NOD-, LRR- and pyrin domain-containing protein 3) NLRP3 inflammasome. We employ computationally guided medicinal chemistry approaches to develop novel, potent, selective, safe, and brain-penetrant NLRP3 inflammasome inhibitors. Our lead compound, AMS-17, has demonstrated promising preclinical activity in attenuating neuroinflammation across these disease models. Building on this foundation, our current efforts are focused on developing next-generation preclinical candidates inspired by the AMS-17 scaffold, with the goal of improving their pharmacological properties and therapeutic potential
Relation to addiction studies
Dr. Kulkarni’s research is focused on the role of neuroinflammation in substance use disorders (SUD). Microglia-mediated activation of the NLRP3 inflamamsome is a salient feature associated with SUDs. This chronic activation leads to the release of pro-inflammatory mediators, including interleukin-1β (IL-1β). Sustained neuroinflammatory signaling may contribute to neuronal dysfunction and neurological consequences associated with substance abuse. Our research uses computational medicinal chemistry and drug design approaches to develop small molecules that inhibit NLRP3 inflammasome activity and potentially mitigate substance-associated neuroinflammation. In a recent collaborative study, we demonstrated that AMS-17 and its structurally modified analogue AMS-4 attenuate cocaine-induced NLRP3 inflammasome signaling in microglial cells. These findings support further investigation of NLRP3 as a potential therapeutic target for addressing neuroinflammation associated with substance abuse.
Research questions
Our research addresses the following questions:
- How does substance abuse contribute to activation of the NLRP3 inflammasome and neuroinflammatory responses in microglial cells?
- Can selective small-molecule inhibitors of the NLRP3 inflammasome attenuate substance-induced inflammatory signaling?
- How do structural modifications to the AMS-17 scaffold influence the biological activity of NLRP3 inhibitors?
- Can medicinal chemistry optimization improve the potency, selectivity, safety, and brain penetration of these compounds to support their further development as potential therapeutic candidates for substance abuse-associated neuroinflammation?
Significance of the work
Substance use disorders are associated with significant neurological and neuropsychiatric consequences, yet effective pharmacological treatment options remain limited. Understanding the molecular mechanisms linking substance exposure to neuroinflammation may reveal new opportunities for therapeutic intervention. Our work focuses on the NLRP3 inflammasome, an important regulator of inflammatory signaling in microglia. In our recent study, AMS-17 reduced cocaine-induced expression of NLRP3 inflammasome components and downstream inflammatory mediators, including IL-1β. Further medicinal chemistry optimization identified AMS-4, which demonstrated pronounced inhibition of cocaine-induced NLRP3 inflammasome activation in microglial cells. Unlike AMS-17, AMS-4 primarily affected the inflammasome assembly and activation phase without suppressing upstream NF-κB-dependent priming. These findings provide a foundation for developing and optimizing small-molecule NLRP3 inhibitors. Ultimately, this research may contribute to new therapeutic strategies aimed at reducing neuroinflammation and its neurological consequences in individuals with substance use disorders. Further studies are needed to establish the efficacy, safety, and therapeutic potential of these compounds in vivo.
Methods to be learned
Dr. Kulkarni’s laboratory combines synthetic organic and medicinal chemistry. The students will learn how to design small molecules based on established pharmacological targets and structure–activity relationships (SAR), plan multistep synthetic routes, and carry out organic chemical reactions using appropriate laboratory techniques. Students will gain experience in reaction monitoring, product isolation, purification using techniques such as column chromatography, and assessment of compound purity. They will also learn to characterize synthesized compounds using spectroscopic and analytical methods, including nuclear magnetic resonance (NMR), infrared (IR) spectroscopy, and mass spectrometry. Through these activities, students will develop a foundation in chemical synthesis, molecular design, purification, and structural characterization, while gaining an appreciation of how medicinal chemistry contributes to the discovery and development of potential therapeutics for addiction-associated neuroinflammation.